Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

Outcomes of Transplant-Eligible and Transplant-Ineligible Patients with Mantle Cell Lymphoma in Ontario, Canada

Adam Suleman, Zharmaine Ante, Ning Liu, Michael Crump, Kelvin KW Chan, Matthew C. Cheung, Anca Prica

Blood (2023) 142 (Supplement 1): 1665.

https://doi.org/10.1182/blood-2023-177788

Published: 2023

Journal Articles

Frailty Impact on Outcomes of Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Anca Prica, Tiana Coley, Rachel Aitken, Abi Vijenthira, Manjula Maganti, Samantha J Mayo, John Kuruvilla, Michael Crump, Sita D. Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir MH Alibhai, Christine Chen

Blood (2023) 142 (Supplement 1): 3768.

https://doi.org/10.1182/blood-2023-189154

Published: 2023

Journal Articles

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

David Hodgson, Mahmood Aminilari, Donna Liao, Xiang Y Ye, Ur Metser, Michael Crump, John Kuruvilla, Abi Vijenthira, Vishal Kukreti, Robert Kridel, Richard Tsang, Sita D. Bhella, Danielle Rodin, Anca Prica

Blood (2023) 142 (Supplement 1): 988.

https://doi.org/10.1182/blood-2023-190983

Published: 2023

Journal Articles

Considering Older Patients As Candidates for Auto Stem Cell Transplants: A Comprehensive Study on Toxicities and Survival Analysis

Miri Zektser, Katrina Hueniken, Michael Crump, Anca Prica, John Kuruvilla, Robert Kridel, Rodger E. Tiedemann, Armand Keating, Vishal Kukreti

Blood (2023) 142 (Supplement 1): 4964.

https://doi.org/10.1182/blood-2023-174816

Published: 2023

Journal Articles

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Samantha J Mayo, Kim Edelstein, Lori Bernstein, Tiana Coley, Stacey Morrison, Abi Vijenthira, Manjula Maganti, John Kuruvilla, Michael Crump, Sita D. Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir MH Alibhai, Christine Chen, Anca Prica

Blood (2023) 142 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2023-190650

Published: 2023

Journal Articles

Indolent Lymphoma Care Delivery and Outcomes during the COVID-19 Pandemic in Ontario, Canada

Inna Gong, Anca Prica, Zharmaine Ante, Andrew Calzavara, Monika Krzyzanowska, Simron Singh, Adam Suleman, Matthew C. Cheung, Michael Crump

Blood (2023) 142 (Supplement 1): 7386.

https://doi.org/10.1182/blood-2023-181296

Published: 2023

Journal Articles

Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study

Esther Bronwyn Ting, Sahar Khan, Manjula Maganti, Sita Bhella, Michael Crump, David C. Hodgson, Robert Kridel, Vishal Kukreti, John Kuruvilla, Danielle Rodin, Richard Tsang, Anca Prica

Blood (2022) 140 (Supplement 1): 3781–3782.

https://doi.org/10.1182/blood-2022-166118

Published: 2022

Journal Articles

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP

Douglas A. Stewart, Lois E. Shepherd, Jill J. Dudebout, Jean-François Larouche, Neil Chua, Tara Baetz, Michael Crump, Mona Shafey, Nizar Abdel-Samad, Sue Robinson, Isabelle Fleury, Deborah Marcellus, Pamela Skrabek, Jesse Kelly, Annette E. Hay, Bingshu Chen, John Kuruvilla

Blood (2022) 140 (Supplement 1): 3734–3736.

https://doi.org/10.1182/blood-2022-163706

Published: 2022

Journal Articles

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Blood (2022) 140 (Supplement 1): 9259–9260.

https://doi.org/10.1182/blood-2022-169623

Published: 2022

Journal Articles

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3500–3503.

https://doi.org/10.1182/blood-2022-168002

Published: 2022

Journal Articles

Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Anca Prica, Tiana Coley, Rachel Aitken, Abi Vijenthira, Manjula Maganti, Samantha J Mayo, Christine I. Chen, John Kuruvilla, Michael Crump, Sita Bhella, Robert Kridel, Vishal Kukreti, Chloe Yang, Shabbir Alibhai

Blood (2022) 140 (Supplement 1): 8028–8029.

https://doi.org/10.1182/blood-2022-170204

Published: 2022

Journal Articles

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Tomasz Wrobel, Fritz Offner, Kathryn Humphrey, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Ben Byrne, Naseer Qayum, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 178–180.

https://doi.org/10.1182/blood-2022-157777

Published: 2022

Journal Articles

Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Blood (2022) 140 (Supplement 1): 3532–3533.

https://doi.org/10.1182/blood-2022-156571

Published: 2022

Journal Articles

Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience

Farheen Manji, Eric Chow, Alina S. Gerrie, Neil Chua, Robert Puckrin, Douglas A. Stewart, Pamela Skrabek, Isabelle Bence-Bruckler, Mary-Margaret Keating, Joanne Britto, Gwynivere A Davies, Vishal Kukreti, John Kuruvilla, Michael Crump

Blood (2021) 138 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2021-146036

Published: 2021

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings

Blood (2021) 138 (Supplement 1): 2479.

https://doi.org/10.1182/blood-2021-147780

Published: 2021

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Anca Prica, Vinita Dhir, Rachel Aitken, Harminder K Paul, Osvaldo Espin-Garcia, Sita Bhella, Christine I. Chen, Michael Crump, Robert Kridel, Vishal Kukreti, John Kuruvilla, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel

Blood (2021) 138 (Supplement 1): 3055.

https://doi.org/10.1182/blood-2021-153120

Published: 2021

Journal Articles

Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial

Abi Vijenthira, Xinzhi Li, Michael Crump, Annette E. Hay, Lois E. Shepherd, Ralph Meyer, Marina S. Djurfeldt, Bingshu E. Chen, Anca Prica

Blood (2021) 138 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2021-153037

Published: 2021

Journal Articles

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Ho-Young Yhim, Yael Eshet, Ur Metser, Katherine Lajkosz, Matthew Cooper, Anca Prica, Vishal Kukreti, Sita Bhella, Noemie Lang, Wei Xu, Danielle Rodin, David Hodgson, Richard Tsang, Michael Crump, John Kuruvilla, Robert Kridel

Blood (2021) 138 (Supplement 1): 1383.

https://doi.org/10.1182/blood-2021-148942

Published: 2021

Journal Articles

Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

Sharon Ben Barouch, Tracy Lackraj, Jessie Medeiros, Mehran Bakhtiari, Jesse Joynt, Kit Tong, Andrea Arruda, Mark D. Minden, Mileidys Alvarez, John Kuruvilla, Sita Bhella, Vishal Kukreti, Michael Crump, Anca Prica, Christine I. Chen, Armand Keating, John E. Dick, Sagi Abelson, Robert Kridel

Blood (2021) 138 (Supplement 1): 655.

https://doi.org/10.1182/blood-2021-150102

Published: 2021

NARROW

Outcomes of Transplant-Eligible and Transplant-Ineligible Patients with Mantle Cell Lymphoma in Ontario, Canada

Frailty Impact on Outcomes of Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Management and Outcomes for Primary Mediastinal B-Cell Lymphoma Patients with Partial Metabolic Response

Considering Older Patients As Candidates for Auto Stem Cell Transplants: A Comprehensive Study on Toxicities and Survival Analysis

Neurocognitive Outcomes over the First 3 Months after Chimeric Antigen Receptor T-Cell (CAR T) Therapy: Preliminary Findings from a Longitudinal Study

Indolent Lymphoma Care Delivery and Outcomes during the COVID-19 Pandemic in Ontario, Canada

Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation

Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Development and Testing of a Lymphoma Clinical Trials Specific Frailty Index: A Secondary Analysis of the LY.12 Clinical Trial

Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume

Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only